Figure 6 | Scientific Reports

Figure 6

From: A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody

Figure 6

Quantification of ZGGS15-induced cytokine release from human immune cells in a human PBMC-based in vitro model relevant to CRS. (A) Human PBMCs were plated at high density and cultured for 48 h. Afterwards, OKT3 (10 nM), anti-irrelevant antigen (anti-HEL IgG4, 5000 nM) or a serial dilution of the antibodies ZGGS15 or Relatlimab analogs were added to the culture. Supernatants were collected 24 h after treatment, and the cytokines were measured by ELISA. Each dot represents one donor, and the line is placed at the median. (B) PBMCs from four different donors were added to antibody-coated plates (plate-bound) and cytokine production was quantified after 48 h. E Each dot represents an individual donor, with the line indicating the median. OKT3 and TGN1412 were used as positive controls since both antibodies have induced CRS in a high percentage of patients in their respective clinical trials, while the anti-HEL IgG4-treated group was used to quantify cytokine production in the absence of stimulation (isotype control).

Back to article page